Pergoveris
Generic Name
follitropin alfa and lutropin alfa
Manufacturer
Merck Serono
Country
Germany
Loading images...
Description
Overview of the medicine
A combination of recombinant human FSH and LH used to stimulate follicular development in women undergoing assisted reproductive technologies (ART) who have severe LH deficiency.
Uses & Indications
Dosage
Adults
Initial dose typically 150 IU follitropin alfa and 75 IU lutropin alfa daily, adjusted based on ovarian response and serum estradiol levels. Treatment duration is usually 7-14 days.
Elderly
Not indicated for elderly women (post-menopausal) as fertility treatment is not appropriate.
Renal_impairment
Not specifically studied in patients with renal impairment; caution and close monitoring are advised.
How to Take
Administered by subcutaneous injection. Patients may be trained for self-administration after initial supervision by a healthcare professional.
Mechanism of Action
Follitropin alfa stimulates follicular growth, and lutropin alfa provides LH activity necessary for optimal follicular development and steroidogenesis.
Pharmacokinetics
Onset
FSH effects usually within days, LH effects are immediate.
Excretion
Primarily renal.
Half life
Follitropin alfa: ~18-24 hours; Lutropin alfa: ~10-12 hours.
Absorption
Subcutaneous administration results in approximately 60-70% bioavailability.
Metabolism
Catabolized in the kidney.
Side Effects
Contraindications
- •Hypersensitivity to the active substances or to any of the excipients.
- •Tumors of the hypothalamus or pituitary gland.
- •Primary ovarian failure.
- •Unexplained vaginal bleeding.
- •Ovarian cysts or enlarged ovaries not due to Polycystic Ovarian Syndrome (PCOS).
- •Carcinoma of the ovary, uterus, or breast.
- •Pregnancy and lactation.
Drug Interactions
GnRH agonists/antagonists
Concurrent use may require a higher dose of Pergoveris to achieve the desired ovarian response.
Storage
Store in a refrigerator (2°C - 8°C). Do not freeze. Protect from light. Once reconstituted, use immediately.
Overdose
The effects of Pergoveris overdose are unknown, but Ovarian Hyperstimulation Syndrome (OHSS) is a potential risk. Symptomatic treatment and monitoring are recommended.
Pregnancy & Lactation
Contraindicated during pregnancy and lactation. Pergoveris should not be used in pregnant or breastfeeding women.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2 to 3 years when stored as recommended. Refer to the specific product packaging for exact expiry date.
Availability
Hospitals, fertility clinics, specialized pharmacies
Approval Status
Approved by EMA and other regulatory bodies
Patent Status
Patent expired for original formulation
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in